Skip to Content

Posts tagged with "Cardiovascular Disease"

  • Cardiovascular Disease

    A Low-Cholesterol Vaccination?

    We have dueling PCSK9 antibodies on the market – Praluent (alirocumab) and Repatha (evolocumab) – and they’re both out there lowering LDL levels as we speak. (Whether these have the desired long-term outcomes remains to be seen; there’s no other way to find out than to wait and watch). But there’s another approach to t… Read More
  • Cardiovascular Disease

    CETP Failure: Now It’s Lilly’s Turn

    It’s been a while since CETP came up on this site as a drug target. This has been many companies’ best shot at an HDL-raising therapy, to go along with the LDL-lowering effects of the statins (and now the PCSK9 inhibitors). The prospect of a two-front attack on cardiovascular disease (and the cardiovascular disease market) Read More
  • Alzheimer's Disease

    Prions In the News (Unfortunately)

    Let’s talk about proteins for a few minutes – nasty, unfriendly proteins, of the sort that will ball up and crash out of solution the first chance they get. Anyone working in a protein purification lab will have encountered plenty of these, and will be familiar with the various tricks available to keep things in… Read More
  • Cardiovascular Disease

    PCSK9 In the Details

    The PCSK9 inhibitors are a class of drugs from which great things are expected. The first ones hitting the market are antibodies, and blocking this enzyme, which is involved in cholesterol homeostasis, clearly has major effects on circulating LDL levels. There are a lot of approaches to going after this target, in the lab, the… Read More
  • Cardiovascular Disease

    Clinical Trials: Getting Much Worse, or Much Better?

    Here’s a very interesting overview of the clinical trials funded (55 total) by the National Heart, Lung, and Blood Institute (NHLBI) over the years 1970-2012. Breaking them into pre-2000 and post-2000 shows something dramatic: in the 30 older trials, 57% of them reported a positive, beneficial outcome. Of the 25 newer ones, only 8% came back… Read More
  • Cardiovascular Disease

    PCSK9 at the FDA

    So an FDA advisory committee met yesterday to consider the PCSK9 antibody from Regeneron and Sanofi, and today it’s the turn of Amgen’s candidate. These, as anyone with even a passing interest in cardiovascular medicine will know, are potential gigantic blockbusters and advances in the field, promising to lower LDL across a huge swath o… Read More
  • Cardiovascular Disease

    Defibrillating Dalcetrapib

    In 2012, Roche halted development of their CETP inhibitor dalcetrapib, part of what (so far) has been a grim chapter in cardiovascular drug development. At the time, this was put down to lack of efficacy, rather than the bad effects seen with Pfizer’s torcetrapib, news that did nothing to cheer up the CETP research community. Read More
  • Cardiovascular Disease

    How Not to Handle Your Clinical Data

    We turn now to Orexigen, one of the small companies trying to make headway in the obesity market. Earlier this year, a patent application from them published, claiming that their drug (Contrave, a sustained release formulation combining the known drugs naltrexone and bupropion) had cardiovascular benefits above and beyond its weight-loss effects. P… Read More
  • Cardiovascular Disease

    Amgen Claims It All

    There’s plenty of excitement about PCSK9, the latest LDL-lowering pathway to make it deep into the clinic. You can tell that companies (and investors) have high hopes for it, since it’s heading right into a market that’s dominated by generic statins. The optimism may well be justified – for example, Sanofi and Regeneron rece… Read More
  • Cardiovascular Disease

    Vytorin Actually Works

    The data from the IMPROVE-IT trial on cardiovascular outcomes for Vytorin have been released. And the combination met the primary endpoint: fewer heart attacks and strokes compared to those already on statin therapy alone. Matthew Herper has an excellent roundup of the results and their context. The effect is real, but it’s not gigantic, eith… Read More
...234...